Rupinderjit Kaur

Rupinderjit Kaur has a strong background in scientific research. Rupinderjit began their career as a Laboratory Research Assistant at the University of Massachusetts Amherst from September 2014 to May 2015. Rupinderjit then worked as a Dissectionist at the Harvard Tissue Brain Resource Center from June 2017 to July 2018. From June 2016 to August 2018, Rupinderjit served as a Research Assistant at McLean Hospital, initially as a Research Assistant I and then later as a Research Assistant II. Rupinderjit joined Sigilon Therapeutics, Inc. in August 2018 as an Associate Scientist in Islet Cell Therapy, and was later promoted to Senior Associate Scientist in January 2020. Rupinderjit then moved to Voyager Therapeutics, Inc. in July 2020 as a Senior Associate Scientist in Vector Engineering, and in January 2022, they took on the role of Senior Associate Scientist II in Novel Capsid Discovery.

Rupinderjit Kaur's education history begins in 2012 when they attended the University of Massachusetts Amherst, where they earned their Bachelor's degree in Biology. From 2019 to 2021, Rupinderjit pursued a Master of Science degree in Biomedical Informatics at The George Washington University School of Medicine and Health Sciences. Currently, they are enrolled in The Johns Hopkins University - Carey Business School, pursuing a Master of Business Administration (MBA) with a focus on Health Care Management, Innovation, and Technology. Their expected graduation date is in 2024.